-
May 03, 2023
SeQure Dx to present at American Society of Gene and Cell Therapy (ASGCT) on the importance of incorporating population heterogeneity evaluation into gene editing and cell therapy off-target analyses
SeQure Dx, Inc, a leading genomics intelligence company, announced today it will present new data at the 2023 American Society of Gene and Cell Therapy Annual Meeting from May 16 - 20 in Los Angeles. Population heterogeneity, or the presence of genomic variants in the population, confers sizable risks to therapy programs due to the [...] -
November 16, 2022
SeQure Dx emerges from stealth mode to fulfill the promise of on-target gene editing therapies for biopharma partners, physicians, and patients
Building on Dr. J. Keith Joung’s ONE-seq platform, SeQure Dx has developed a portfolio of assays and data solutions to find, assess, and manage off-target risks from discovery to clinical development to patient impact.
-
August 03, 2021
SeQure Dx Announces $17.5M Series A Funding
Patented technology addresses emerging need for personalized diagnostics that assess the risks of gene-editing therapies